CBD New Food Regulations France

DGAL/DGCCRF offensive: CBD officially banned from standard food supplement status

In April 2026, the French CBD market is going through one of the most decisive turning points in its history. After years spent in a regulatory grey area, ingestible products – sublingual oils, gummies, infusions and enriched foodstuffs – are entering a new era of control.

The Directorate-General for Food (DGAL) and the Directorate-General for Competition, Consumer Affairs and Fraud Control (DGCCRF) have launched a coordinated offensive on an unprecedented scale, fundamentally redefining the rules of the game for the entire sector.

This tightening, prepared over several months and made official at a meeting held on 15 April 2026 with the trade associations, is based on a strict application of the European regulation (EU) 2015/2283 on novel foods (Novel Food).

In practical terms, CBD loses its standard food supplement status and moves into an ingredient category awaiting European validation, a change with direct consequences for packaging, taxation, distribution and marketing communication.

Here is everything you need to understand to stay on the right side of the rules, whether as an informed consumer or an industry professional.

1. The end of health claims: CBD must fall into line

It is now official: health claims on CBD products are officially prohibited. The claims that long structured the sector’s communication, “sleep aid”, “anti-stress”, “pain relief”, “relaxing effect” or “anti-inflammatory action”, are gradually disappearing from labels, product sheets and marketing materials.

This ban is not new in principle. It stems from Regulation (EC) No 1924/2006, which strictly regulates nutrition and health claims for all foodstuffs sold in Europe. But with CBD’s move into the category of unauthorised Novel Food, the DGCCRF now applies zero tolerance. Any claim suggesting a therapeutic or functional benefit may now result in an official report, a formal notice and withdrawal of the product.

For brands, this means a complete overhaul of packaging. Packaging must adopt a total neutrality : product name, composition, CBD dosage, indication of the THC level (below 0.3%), legal warnings. No more promises, facts come first.

This measure also protects the consumer. Its aim is to prevent CBD from being presented as a medicinal alternative, when no Novel Food application has so far been validated by the EFSA (European Food Safety Authority). Until this validation, commercial messaging must remain factual and descriptive.

2. The locking of the Compl’Alim platform: an administrative bottleneck

To legally market a food supplement in France, each operator must submit a declaration file via the Compl’Alim platform (formerly TéléIcare), managed by the DGAL. This procedure, mandatory since 2006, allows the authorities to check the product’s compliance before it is placed on the market.

Now, the new guidelines issuing from the meeting of 15 April 2026 are unequivocal: files containing CBD are now almost systematically blocked. The reason is simple: cannabidiol still does not appear on the positive list of novel foods authorised by the European Union, and no authorisation has been issued since 2023. The evaluation procedure is officially at a standstill.

Direct consequence for the industry: hundreds of products, gummies, sublingual oils, enriched herbal teas, capsules, find themselves in a situation of technical non-compliance. They may be present on the shelves, but they have no valid declaration certificate. And without a certificate, DGCCRF inspections can trigger immediate withdrawals.

The timetable is tight: the coordinated national inspection campaign starts in mid-May 2026. It will apply to all distribution channels: specialist shops, supermarkets, pharmacies, parapharmacies, vending machines and online shops. No player is spared.

For professionals, this requires a urgent review of catalogues. Ingestible products without a validated file must be withdrawn from sale or reformulated to leave the “food supplement” category and enter an alternative category (cosmetic, smoking product, seeds, etc.), each with its own regulatory requirements.

3. Harmonised taxation: 20% VAT applies to everyone

The tax uncertainty that has prevailed around CBD for years is now lifted. Bercy has ruled: the applicable VAT rate is 20%, across the entire chain, from producer to retailer, for all categories of cannabidiol products.

This clarification puts an end to an inconsistent practice in which some operators applied the reduced rate of 5.5% to raw flowers (treated as an agricultural product) or to certain ingestible products, while others applied the standard rate of 20%. The result: sometimes significant price differences between retailers, and a high risk of tax reassessment for the least cautious operators.

From now on, the guidance is unified. Oils, gummies, flowers, resins, e-liquids, cosmetics and infusions are all subject to the standard rate of 20%. This decision is in line with most neighbouring European countries and aims to normalise CBD alongside other everyday consumer products.

Direct impact for consumers : an automatic rise in displayed prices, particularly for products previously sold under the reduced rate. Shops that applied 5.5% to their flowers are seeing their prices rise by around 14 points. For professionals, this also means a risk of reassessment covering the last three years, with payment of the VAT differential and associated penalties. Early regularisation is strongly recommended.

As a reminder, this measure should not be confused with the provisions of the Draft Finance Bill 2026 (Article 23), which provides for an additional “excise duty”-type tax on inhalable products (flowers and resins), along the lines of the tax regime applied to tobacco. This aspect is still the subject of parliamentary debate and strong opposition from industry professionals.

Dossier: VAT rates in a CBD shop: the products at 20% you need to know

4. Strengthened safety: zero tolerance on THC levels

The fourth pillar of this regulatory offensive concerns health safety, with an intensification of analytical checks on THC levels. The legal threshold of 0.3% THC in hemp-based products remains unchanged, but the control procedures are becoming markedly stricter.

The authorities now rely on the concept of “acute reference dose”, a toxicological measure that sets the maximum amount of THC a consumer can ingest in a single intake without risk to health. If testing detects even the slightest excess, the product is immediately withdrawn from the market and reported via the official platform RappelConso, which can be consulted by the general public.

These withdrawals, which were previously occasional, are becoming standard procedure. Each non-compliant batch can lead to an official publication, with a direct effect on the brand’s reputation and an obligation for distributors to physically remove the products from the shelves. Penalties may be accompanied by fines and, in the most serious cases, criminal prosecution.

For operators, this development requires a impeccable traceability : testing by accredited laboratories for every batch, complete supplier documentation, compliance with authorised varieties (listed in the European seed catalogue), and rigorous archiving of certificates of analysis. The slightest lapse is now penalised.

Partner file: For tobacconists, here are the mandatory legal obligations for selling CBD.

What to remember: CBD is leaving the Wild West

The combined offensive by the DGAL and the DGCCRF marks the definitive end of an era for the French CBD market. The years of tolerance and grey area, during which each operator could interpret the regulation in their own way, are over. The sector is entering an era of high security, transparency and strict compliance.

For consumers, these changes translate concretely into:

  • From streamlined packaging, without health promises, with purely factual information
  • From rising prices on certain categories, due to the alignment with 20% VAT
  • An reduced availability of certain ingestible products, notably undeclared gummies and oils
  • An better health protection, with reinforced controls on THC levels

For professionals, the priority now is urgent compliance : reviewing packaging, auditing Compl’Alim files, regularising tax positions, strengthening traceability procedures. The cost of this adaptation is real, but the long-term viability of the business depends on it.

If your usual products change appearance or price, or temporarily disappear from the shelves, you now know why. French CBD is entering a new era, more demanding, but also potentially more robust and more sustainable. It remains to be seen whether the European framework will finally settle the question of Novel Food status once and for all, and whether a balanced compromise can emerge between consumer protection and the economic viability of an entire sector.

en_GB